A nationwide, multicenter, case-control study comparing risk factors, treatment, and outcome for vancomycin-resistant and -susceptible enterococcal bacteremia

被引:142
|
作者
Bhavnani, SM
Drake, JA
Forrest, A
Deinhart, JA
Jones, RN
Biedenbach, DJ
Ballow, CH
机构
[1] Millard Fillmore Hosp, Clin Pharmacokinet Lab, Kaleida Hlth, Buffalo, NY 14209 USA
[2] Univ Iowa, Coll Med, Dept Pathol, Iowa City, IA 52242 USA
关键词
enterococcus; resistance; bacteremia; classification and regression tree analysis; nosocomial pathogens;
D O I
10.1016/S0732-8893(99)00136-4
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
National Nosocomial Resistance Surveillance Group participants from 22 hospitals across the United States reviewed medical records for hospitalized patients with vancomycin-resistant enterococcal (VRE) or vancomycin-susceptible enterococcal (VSE) bacteremia to identify risk factors associated with the acquisition of VRE bacteremia, describe genetic traits of VRE strains, and identify factors predictive of clinical outcome. VRE cases were matched to VSE controls within each institution. Multiple logistic regression (LR) and classification and regression tree (CART) analysis were used to probe for factors associated with VRE bacteremia and clinical outcome. A total of 150 matched-pairs of VRE cases and VSE controls were collected from 1995 to 1997. Using LR, the following were found to be highly associated with VRE bacteremia: history of AIDS, positive HIV status, or drug abuse (OR 9.58); prior exposure with parenteral vancomycin (OR 8.37); and liver transplant history (OR 6.75). CART analysis revealed that isolation of Enterococcus faecium, prior vancomycin exposure, and serum creatinine values greater than or equal to 1.1 mg/dl were predictors of VRE bacteremia. Greater proportions of clinical failure (60% versus 40%, P < 0.001) and all-cause mortality (52% versus 27%, P < 0.001) were seen in patients with VRE versus VSE bacteremia. Results from both LR and CART indicated that patients with persisting enterococcal bacteremia, intubation at baseline, higher APACHE II scores, and VRE bacteremia were at greater risk for poor outcome. (C) 2000 Elsevier Science Inc. All rights reserved.
引用
下载
收藏
页码:145 / 158
页数:14
相关论文
共 50 条
  • [21] Contemporary Clinical and Molecular Epidemiology of Vancomycin-Resistant Enterococcal Bacteremia: A Prospective Multicenter Cohort Study (VENOUS I)
    Contreras, German A.
    Munita, Jose M.
    Simar, Shelby
    Luterbach, Courtney
    Dinh, An Q.
    Rydell, Kirsten
    Sahasrabhojane, Pranoti, V
    Rios, Rafael
    Diaz, Lorena
    Reyes, Katherine
    Zervos, Marcus
    Misikir, Helina M.
    Sanchez-Petitto, Gabriela
    Liu, Catherine
    Doi, Yohei
    Abbo, Lilian M.
    Shimose, Luis
    Seifert, Harald
    Gudiol, Carlota
    Barberis, Fernanda
    Pedroza, Claudia
    Aitken, Samuel L.
    Shelburne, Samuel A.
    Duin, Davidvan
    Tran, Truc T.
    Hanson, Blake M.
    Arias, Cesar A.
    OPEN FORUM INFECTIOUS DISEASES, 2022, 9 (03):
  • [22] Risk factors and outcomes associated with persistent vancomycin resistant Enterococcal Bacteremia
    Emily Fox
    David Ha
    Mark Bounthavong
    Lina Meng
    Emily Mui
    Marisa Holubar
    Stanley Deresinski
    William Alegria
    BMC Infectious Diseases, 22
  • [23] Risk factors and outcomes associated with persistent vancomycin resistant Enterococcal Bacteremia
    Fox, Emily
    Ha, David
    Bounthavong, Mark
    Meng, Lina
    Mui, Emily
    Holubar, Marisa
    Deresinski, Stanley
    Alegria, William
    BMC INFECTIOUS DISEASES, 2022, 22 (01)
  • [24] Daptomycin Therapy for Vancomycin-Resistant Enterococcal Bacteremia: A Retrospective Case Series of 30 Patients
    Gallagher, Jason C.
    Perez, Mirza E.
    Marino, Elizabeth A.
    LoCastro, Laura G.
    Abrardo, Lauren A.
    MacDougall, Conan
    PHARMACOTHERAPY, 2009, 29 (07): : 792 - 799
  • [25] Successful treatment of vancomycin-resistant enterococcal bacteremia using combination antibiotic therapy.
    Dominguez, ER
    Diaz, A
    Greene, JN
    Sandin, RL
    CLINICAL INFECTIOUS DISEASES, 1996, 23 (04) : 169 - 169
  • [26] Impact of vancomycin-resistant enterococcal bacteremia on outcome during acute myeloid leukemia induction therapy
    Ornstein, Moshe C.
    Mukherjee, Sudipto
    Keng, Michael
    Elson, Paul
    Tiu, Ramon V.
    Saunthararajah, Yogenthiran
    Maggiotto, Amanda
    Schaub, Madeline
    Banks, Diane
    Advani, Anjali
    Kalaycio, Matt
    Maciejewski, Jaroslaw P.
    Sekeres, Mikkael A.
    LEUKEMIA & LYMPHOMA, 2015, 56 (09) : 2536 - 2542
  • [27] Risk factors for development of vancomycin-resistant enterococcal bloodstream infection in patients with cancer who are colonized with vancomycin-resistant enterococci
    Zaas, AK
    Song, XY
    Tucker, P
    Perl, TM
    CLINICAL INFECTIOUS DISEASES, 2002, 35 (10) : 1139 - 1146
  • [28] Risk factors for methicillin-resistant Staphylococcus aureus bacteremia: A multicenter matched case-control study
    Arias-Ortiz, Paola Mariana
    Calderon, Libia del Pilar
    Castillo, Juan Sebastian
    Moreno, Jose
    Leal, Aura Lucia
    Cortes, Jorge Alberto
    Alvarez, Carlos Arturo
    BIOMEDICA, 2016, 36 (04): : 612 - 618
  • [29] Treatment and outcome of vancomycin-resistant enterococcal infection in liver transplant recipients with linezolid
    Linden, PK
    Kramer, DJ
    Birmingham, MC
    Kusne, S
    CLINICAL INFECTIOUS DISEASES, 2000, 31 (01) : 278 - 278
  • [30] Vancomycin-resistant enterococci bacteremia: Risk factors for mortality and influence of antimicrobial therapy on clinical outcome
    Han, Sang Hoon
    Chin, Bum Sik
    Lee, Han Sung
    Jeong, Su Jin
    Choi, Hee Kyoung
    Kim, Chang Oh
    Yong, Dongeun
    Choi, Jun Yong
    Song, Young Goo
    Lee, Kyungwon
    Kim, June Myung
    JOURNAL OF INFECTION, 2009, 58 (03) : 182 - 190